Shares of Moderna (NASDAQ:MRNA) are up roughly 6% in Monday morning trading, changing hands near $57.52 after Friday’s close of $54.35. The intraday move extends what has already been a powerful 2026 ...

Pfizer (NYSE:PFE) and Moderna (NASDAQ:MRNA) just closed the books on Q4 2025, and the contrast is striking. Pfizer leaned on a diversified non-COVID portfolio and a fresh push into obesity drugs.

Despite a U.S. factory mixup, more Johnson & Johnson doses are becoming available in the U.S., marking the only single-shot vaccine option. So how effective is it and how does it compare to the Pfizer ...

The smaller, more volatile of these two companies has higher potential for significant gains. However, that also comes with a healthy dose of risk. Choosing between these two stocks may come down to ...

Shares in Pfizer and Moderna fell 3.9% and 7.4%, respectively, Friday after a report that the Trump administration plans to link the deaths of 25 children to COVID vaccines. Trump health officials ...

Amid uncertainty over how the Trump administration would approach mRNA COVID-19 vaccines for the upcoming respiratory virus season, the FDA has approved updated shots from Pfizer and Moderna. But ...

Pfizer (PFE) posted Q4 adjusted EPS of $0.66 beating the $0.57 consensus on $17.56B in revenue while its non-COVID portfolio grew 9% operationally, led by Abrysvo (+136%) and Lorbrena (+45%), plus a ...